Protein & Cell Impact Factor

The first useful signal is that Protein & Cell is stronger than many authors still assume. It publishes at relatively low volume, but it attracts citation performance that looks more like a selective upper-tier biology title than a quiet broad-scope journal.

The second useful signal is durability. The five-year JIF of 19.5 is far above the current JIF, which tells you the journal's better papers keep working long after the short citation window passes. That usually happens when articles become durable reference points instead of short-lived trend papers.

The third useful signal is cleanliness. The JIF without self-cites is 12.5, very close to the reported JIF. That means the headline number is not being propped up by aggressive internal citation behavior.

The SJR of 5.392 and h-index of 82 reinforce that this is not just a one-cycle citation story. The journal has enough long-run citation depth to matter beyond a single year of enthusiasm.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is down from 12.12 in 2023 to 7.91 in 2024. That drop matters, but it needs context. The journal is still operating far above its mid-2010s baseline, and the very high five-year JIF says the better papers retain citation value over time.

The healthier read is that Protein & Cell saw a short-window cooling after a very strong recent phase, not a collapse in relevance.

The common mistake is to see broad scope plus a strong impact factor and assume the journal is forgiving.

That is not how the public author instructions frame it. Protein & Cell publishes across multidisciplinary biology and biomedicine, but editors still actually screen for papers that can travel beyond one narrow specialty and carry a real mechanistic or conceptual point.

In practice, the journal tends to reward manuscripts where:

• the broad consequence is visible early
• the mechanistic support actually carries the claim
• the manuscript still matters outside the exact home subfield
• the package reads as mature and editorially complete on first pass

That means the metric tells you the journal has reach. It does not tell you that a technically respectable niche paper belongs there.

In our pre-submission review work on manuscripts targeting Protein & Cell, the repeat problem is not scientific weakness. It is overestimation of breadth.

We see authors assume that because the scope is broad, the journal will absorb narrow work if the science is solid. Editors actually screen for whether the paper can speak beyond one local audience, and the official one-round-revision posture makes first-read readiness matter more than many authors expect.

In our pre-submission review work on manuscripts targeting Protein & Cell, four failure patterns recur.

The paper is scientifically sound but too self-contained. It works inside one niche, but the wider biology readership case is weak.

The mechanism is thinner than the headline. Strong phenotypes or translational framing often need one more mechanistic layer before the paper reads credibly at this level.

The package still looks unfinished. Because the journal signals relatively fast review and limited revision runway, sloppiness in figures, metadata, or disclosure material hurts early.

The title and abstract undersell the broader consequence. Editors can miss a good paper if the first read does not make the cross-field relevance obvious quickly enough.

If that sounds familiar, a Protein & Cell submission readiness check is usually more useful than another round of sentence cleanup.

The impact factor does not tell you whether the manuscript is broad enough, whether the mechanism is deep enough, or whether the editorial package is mature enough for a journal that moves relatively quickly.

That is where most mismatches happen. The metric places the journal. It does not widen the manuscript's readership case.